At the conference this month, editor-in-chief Jonah Comstock caught up with Scot Ebbinghaus, vice president of clinical research at Merck, who spoke a bit about Keytruda’s anniversary ...

and Merck’s vice president of clinical research, Dr Scot Ebbinghaus, said “we look forward to continuing to advance research [for HCC] across our portfolio with the goal to help even more ...

We sat down with Dr. Scot Ebbinghaus, a medical oncologist and vice president of clinical development at Merck, to learn where research currently stands. Neoantigens are unique proteins that ...